샘플 요청 목록

 카트 문의
시장보고서
상품코드
1564934

세계의 신생아 스크리닝 시장

Newborn Screening
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 158 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신생아 스크리닝 세계 시장은 2030년까지 19억 달러에 달할 것으로 예상됩니다

2023년 12억 달러로 추정되는 신생아 스크리닝 세계 시장은 2030년 19억 달러에 달할 것으로 예상되며, 2023-2030년의 분석 기간 동안 7.1%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다. 신생아 스크리닝 보고서에서 분석한 부문 중 하나인 소모품은 CAGR 7.5%를 기록하여 분석 기간이 끝날 때까지 14억 달러에 도달할 것으로 예상됩니다. 신생아 선별 검사 장비 부문의 성장률은 분석 기간 동안 CAGR 6.3%로 추정됩니다.

미국 시장은 3억 1,380만 달러로 추정, 중국은 CAGR 10.6%로 성장 전망

미국의 신생아 스크리닝 시장은 2023년 3억 1,380만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 4억 6,720만 달러 규모에 도달할 것으로 예상되며, 2023-2030년의 분석 기간 동안 10.6%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 3.6%와 6.4%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 연평균 4.2%의 성장률을 보일 것으로 예상됩니다.

세계 신생아 스크리닝 시장 - 주요 동향 및 촉진요인 요약

신생아 스크리닝이란 무엇이며, 왜 필수적인가?

신생아 스크리닝는 출생 직후 영아를 대상으로 특정 유전질환, 대사질환, 발달장애를 검사하는 중요한 공중보건 프로그램입니다. 이러한 검사는 방치할 경우 발달 지연, 신체 장애, 심지어 사망과 같은 심각한 건강 문제를 초래할 수 있는 질환을 발견하는 데 필수적입니다. 신생아 스크리닝를 통한 조기 발견은 약물치료, 식습관 개선, 수술 등의 개입을 적시에 시행하여 장기적인 합병증을 예방하고 아동의 삶의 질을 향상시킬 수 있습니다.

신생아 스크리닝 프로그램에는 일반적으로 페닐케톤뇨증(PKU), 선천성 갑상선기능저하증, 겸상적혈구증, 낭포성 섬유증 등 다양한 질환에 대한 검사가 포함됩니다. 기술의 지속적인 발전으로 검출 가능한 질병의 범위가 확대되고 있으며, 신생아 스크리닝는 현대 의료에 필수적인 도구가 되고 있습니다. 신생아 스크리닝 프로그램은 이러한 질병을 조기에 발견함으로써 영아 사망률을 낮추고 전반적인 공중 보건을 개선하는 데 기여하고 있습니다.

신생아 스크리닝 시장은 어떻게 진화하고 있는가?

신생아 스크리닝 시장은 기술 발전과 선별검사 패널의 확대로 인해 빠르게 진화하고 있습니다. 시장을 형성하는 중요한 추세 중 하나는 한 번의 혈액 샘플에서 여러 대사 이상을 감지할 수 있는 기술인 MS/MS(Tandem Mass Spectrometry)의 사용이 증가하고 있다는 점입니다. 이 기술은 보다 빠르고 정확하며 종합적인 검사를 가능하게 하여 신생아 선별 검사에 혁명을 일으켰습니다. 또한 차세대 염기서열 분석(NGS)을 포함한 유전자 검사 기술이 신생아 선별 검사 프로그램에 통합되어 희귀질환을 포함한 더 광범위한 유전자 질환을 감지할 수 있게 되었습니다.

또 다른 주요 트렌드는 신생아 스크리닝를 현장 검사(POCT)로 전환하는 것으로, POCT 장비는 휴대가 가능하고 침대 옆에서 즉시 검사 및 결과를 얻을 수 있어 진단된 질병에 대한 치료 시작 시간을 단축할 수 있습니다. 디지털 헬스케어 플랫폼의 확장은 데이터 수집, 분석 및 보고 프로세스를 간소화하여 보다 효율적인 신생아 스크리닝 워크플로우를 가능하게 함으로써 시장의 진화에 일조하고 있습니다. 이러한 발전은 특히 의료 인프라에 대한 접근성이 제한적인 지역에서 더 많은 영아를 더 빠르게 선별할 수 있도록 돕고 있습니다.

어떤 상황이 신생아 스크리닝에 대한 수요를 촉진하고 있는가?

페닐케톤뇨증(PKU)과 선천성 갑상선기능저하증과 같은 대사 이상은 가장 많이 검진되는 질환 중 하나입니다. 이러한 질환은 조기에 발견되지 않으면 심각한 발달 문제를 일으킬 수 있지만, 적절한 개입을 통해 그 영향을 크게 줄일 수 있습니다. 낭포성 섬유증과 겸상 적혈구증과 같은 유전성 질환도 조기 치료를 통해 심각한 합병증을 예방하고 장기적인 건강 결과를 개선할 수 있기 때문에 검진 수요의 큰 원동력이 되고 있습니다.

또한, 라이소좀 저장 장애(LSD)는 희귀 유전 질환의 일종으로 신생아 선별 검사 패널에 포함되는 경우가 많아지고 있습니다. 진단 기술의 발전으로 더 많은 희귀질환이 발견되어 조기 치료를 통해 환자의 예후를 개선할 수 있게 되었습니다. 조기 식이 중재가 필요한 유전성 대사 질환 증가도 전 세계적으로 신생아 스크리닝 프로그램에 대한 수요 증가에 기여하고 있습니다.

신생아 스크리닝 시장의 주요 성장 촉진요인은 무엇인가?

신생아 스크리닝 시장의 성장은 조기 진단과 개입이 필요한 유전성 및 대사성 질환의 유병률 증가 등 여러 요인에 의해 주도되고 있습니다. 신생아 스크리닝 프로그램 확대에 초점을 맞춘 정부의 의무와 이니셔티브는 일상적인 검사에 포함되는 질환 증가를 보장하기 때문에 주요 촉진요인으로 작용하고 있습니다. 특히 질량 분석 및 유전자 시퀀싱의 기술 발전은 보다 종합적이고 정확한 선별 검사를 가능하게 함으로써 시장 성장을 가속하고 있습니다.

또 다른 중요한 요인은 장기적인 건강 합병증 예방에 있어 조기 발견의 중요성에 대한 의료 서비스 제공업체와 보호자의 인식이 높아진 것입니다. 특히 신흥국 시장에서는 의료 인프라가 개선됨에 따라 신생아 스크리닝에 대한 접근성이 확대되어 시장 성장에 기여하고 있습니다. 또한, 공공 의료 기관과 비상장 기업의 협력 관계가 강화되면서 첨단 선별검사 기술의 보급과 환자 예후 개선으로 이어지고 있습니다.

조사 대상 기업 예시(11개사)

  • AB Sciex LLC
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • GE Healthcare
  • Masimo Corporation
  • Medtronic PLC
  • Natus Medical, Inc.
  • PerkinElmer, Inc.
  • Trivitron Healthcare
  • Waters Corporation

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 24.10.08

Global Newborn Screening Market to Reach US$1.9 Billion by 2030

The global market for Newborn Screening estimated at US$1.2 Billion in the year 2023, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2023-2030. Newborn Screening Consumables, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Newborn Screening Instruments segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$313.8 Million While China is Forecast to Grow at 10.6% CAGR

The Newborn Screening market in the U.S. is estimated at US$313.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$467.2 Million by the year 2030 trailing a CAGR of 10.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Newborn Screening Market - Key Trends & Drivers Summarized

What Is Newborn Screening and Why Is It Essential?

Newborn screening is a vital public health program that tests infants for certain genetic, metabolic, and developmental disorders shortly after birth. These screenings are essential for detecting conditions that, if left untreated, can lead to severe health problems, including developmental delays, physical disabilities, and even death. Early detection through newborn screening allows for timely interventions, such as medications, dietary changes, or surgeries, which can prevent long-term complications and improve the child’s quality of life.

Newborn screening programs typically include tests for a variety of conditions, such as phenylketonuria (PKU), congenital hypothyroidism, sickle cell disease, cystic fibrosis, and more. With the continuous advancement in technology, the range of detectable disorders is expanding, making newborn screening an indispensable tool in modern healthcare. By identifying these conditions early, newborn screening programs contribute to reducing infant mortality and improving overall public health outcomes.

How Is the Newborn Screening Market Evolving?

The newborn screening market is evolving rapidly, driven by technological advancements and the expansion of screening panels. One of the key trends shaping the market is the increasing use of tandem mass spectrometry (MS/MS), a technology that allows for the detection of multiple metabolic disorders from a single blood sample. This technology has revolutionized newborn screening by enabling faster, more accurate, and comprehensive testing. Additionally, genetic screening techniques, including next-generation sequencing (NGS), are being integrated into newborn screening programs, allowing for the detection of a broader range of genetic conditions, including rare diseases.

Another significant trend is the shift towards point-of-care testing (POCT) for newborn screening. POCT devices are portable and enable immediate testing and results at the bedside, reducing the time it takes to begin treatment for diagnosed conditions. The expansion of digital healthcare platforms is also playing a role in the evolution of the market by streamlining data collection, analysis, and reporting processes, leading to more efficient newborn screening workflows. This evolution is allowing more infants to be screened faster, particularly in regions where access to healthcare infrastructure may be limited.

Which Conditions Are Driving the Demand for Newborn Screening?

Several conditions are driving the demand for newborn screening, with metabolic disorders such as phenylketonuria (PKU) and congenital hypothyroidism being among the most commonly screened. These conditions can cause serious developmental issues if not detected early, but with appropriate interventions, their impacts can be significantly mitigated. Genetic disorders, such as cystic fibrosis and sickle cell disease, are also major drivers of screening demand, as early treatment can prevent severe complications and improve long-term health outcomes.

Additionally, lysosomal storage disorders (LSDs), which are a group of rare genetic conditions, are increasingly being included in newborn screening panels. As diagnostic technologies improve, more rare diseases are being detected, leading to early treatments that can improve the prognosis for affected children. The rise of inherited metabolic disorders, which require early dietary interventions, is also contributing to the growing demand for newborn screening programs across the globe.

What Are the Key Growth Drivers in the Newborn Screening Market?

The growth in the newborn screening market is driven by several factors, including the increasing prevalence of genetic and metabolic disorders, which necessitate early diagnosis and intervention. Government mandates and initiatives focused on expanding newborn screening programs are a key driver, as they ensure that a growing number of conditions are included in routine testing. Technological advancements, particularly in mass spectrometry and genetic sequencing, are also propelling market growth by enabling more comprehensive and accurate screening.

Another important factor is the rising awareness among healthcare providers and parents about the importance of early detection in preventing long-term health complications. As healthcare infrastructure improves, especially in developing regions, access to newborn screening is expanding, contributing to market growth. Additionally, collaborations between public health organizations and private companies are increasing, leading to more widespread adoption of advanced screening technologies and better patient outcomes.

Select Competitors (Total 11 Featured) -

  • AB Sciex LLC
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • GE Healthcare
  • Masimo Corporation
  • Medtronic PLC
  • Natus Medical, Inc.
  • PerkinElmer, Inc.
  • Trivitron Healthcare
  • Waters Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Newborn Screening - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Early Detection and Prevention Drives Growth in Newborn Screening Programs Globally
    • Increasing Adoption of Genetic and Metabolic Screening Expands Opportunities for Early Diagnosis of Congenital Disorders
    • Technological Advancements in Mass Spectrometry Propel Growth in Newborn Screening for Rare Metabolic Disorders
    • Growing Focus on Early Detection of Cystic Fibrosis and Sickle Cell Disease Strengthens Demand for Newborn Screening
    • Expansion of Government-Funded Newborn Screening Programs Drives Adoption in Public Health Systems Worldwide
    • Increasing Use of Tandem Mass Spectrometry (MS/MS) in Newborn Screening Expands Precision Diagnosis Capabilities
    • Rising Adoption of DNA-Based Screening Technologies for Inherited Disorders Strengthens Market for Genomic Newborn Testing
    • Growing Demand for Point-of-Care Newborn Screening Expands Access to Early Detection in Remote and Low-Income Regions
    • Emerging Focus on Screening for Lysosomal Storage Disorders Propels Innovation in Newborn Screening Assays
    • Increasing Use of Digital Data Management Systems in Newborn Screening Programs Drives Demand for Integrated Solutions
    • Rising Demand for Expanded Newborn Screening for Immunodeficiencies and Endocrine Disorders Expands Addressable Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Newborn Screening Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Newborn Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Dry Blood Spot Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Dry Blood Spot Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Dry Blood Spot Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hearing Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hearing Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hearing Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Immunoassays & Enzymatic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Immunoassays & Enzymatic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Immunoassays & Enzymatic Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Tandem Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Molecular Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Molecular Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hearing Screening Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hearing Screening Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hearing Screening Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Pulse Oximetry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Pulse Oximetry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Pulse Oximetry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • JAPAN
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • CHINA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • EUROPE
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Newborn Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • FRANCE
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • GERMANY
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Newborn Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • INDIA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Newborn Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Newborn Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • AFRICA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제